The Complement System: Activation Pathways, Regulation, and Biological Functions

Historical Discovery and Core Concept of Complement

• Discovery by Jules Bordet:
  • Discovered as a heat-labile component of normal blood serum that augmented and enhanced the opsonization and lysis of bacteria by a heat-stable serum component (antibodies).
  • Demonstrates that immune lysis requires two distinct serum factors working in tandem.

• Nomenclature Origin (Paul Ehrlich):
  • Named "complement" because its enzymatic activity was recognized to complement and complete the antibacterial function of antibodies.
  • While discovered in the context of antibody function, complement can also be activated early during an infection completely independent of antibodies as part of innate immunity.

• Jules Bordet's Landmark Heat-Lability Experiment:
  • Condition 1: Unheated sheep antiserum containing antibacterial antibodies added to bacteria resulted in complete lysis of bacteria.
  • Condition 2: Heating sheep antiserum containing antibacterial antibodies prior to introducing bacteria resulted in no lysis, proving the critical lytic factor is heat-labile.
  • Condition 3: Combining heat-treated antiserum (containing antibodies but inactivated complement) with fresh normal serum containing no antibodies restored lysis of bacteria, confirming that fresh normal serum supplies the heat-labile complement factor.

Structural Overview and General Principles of Complement

• Composition of the System:

  • Composed of a complex network of at least 30 distinct plasma proteins and membrane-bound cell surface receptors.
  • Synthesized predominantly by hepatocytes, as well as circulating macrophages and epithelial cells.

• Zymogen Cascade Architecture:

  • Most complement proteins circulate in blood plasma as inert enzyme precursors termed zymogens.
  • Zymogens become enzymatically active only after controlled proteolytic cleavage.
  • Activation occurs in a sequential cascade fashion, where the active cleavage product of one protein functions as an active protease that cleaves the next zymogen in the pathway.
  • Because activation relies on a strictly ordered sequential cascade, the genetic absence or functional deficiency of even a single component disrupts the entire downstream pathway and terminates activation.

• Surface-Driven Assembly:

  • A primary site for complement cascade activation, assembly, and amplification is the exposed surface of invading pathogens.
  • Sequential protein interactions generate self-assembling enzymatic complexes directly on pathogen membranes, yielding highly active biological effector molecules that mediate full inflammatory and protective responses.

Functional Pathways and Primary Protective Outcomes

• Three Distinct Activation Pathways:
  • Classical Pathway: Triggered primarily by antigen:antibody complexes (a bridge between adaptive and innate immunity).
  • Lectin Pathway: Triggered by lectin binding to specific carbohydrate structures on pathogen surfaces.
  • Alternative Pathway: Triggered directly by pathogen surfaces via low-level spontaneous C3 hydrolysis.

• Convergence and Common Effector Functions:
  • All three distinct activation pathways converge at a central enzymatic step: the generation of a C3 convertase complex that cleaves complement protein C3.
  • Activation culminates in three major innate protective outcomes:
  1. Recruitment of Inflammatory and Immunocompetent Cells (Chemotaxis):
     • Small cleavage fragments ($C3a$, $C5a$, $C4a$) act as soluble chemoattractants (anaphylatoxins).
     • Establish gradient fields attracting neutrophils, eosinophils, and macrophages to sites of activation.

2. **Opsonization of Pathogens**:
   * Large cleavage fragments ($C3b$, $iC3b$, $C4b$) covalently bind directly to microbial cell walls.
   * Phagocytic cells expressing complement receptors (CR) recognize these surface-bound opsonins, resulting in dramatic enhancement of particle phagocytosis.

3. **Direct Target Lysis (Killing of Pathogens)**:
   * Assembly of terminal complement components ($C5b$, $C6$, $C7$, $C8$, $C9$) forms the Membrane Attack Complex (MAC).
   * The MAC inserts into target lipid bilayers, creating open cylindrical pores that disrupt osmotic balance and induce cell lysis.

• Participation in Adaptive Immunity:
  • Antigen Presentation: Opsonization of microbes by complement components allows efficient uptake, internal processing, and presentation by antigen-presenting cells (APCs) such as dendritic cells (DCs).
  • B-Cell Activation: B lymphocytes express specific complement receptors (such as CR2 / CD21) for cleavage fragments like $C3dg$, lowers the threshold for B-cell receptor activation, and promotes long-term immunological memory.

Systematic Nomenclature of Complement Components

• Native Component Naming (Classical & Lectin Pathways):

  • Designated by the capital letter C followed by a number (e.g., C1 through C9).
  • Numbering reflects the historical order of discovery, not the functional sequence of activation.
  • Exact historical discovery order: C1, C4, C2, C3, C5, C6, C7, C8, C9.

• Cleavage Fragment Naming:

  • Products of proteolytic cleavage are indicated by appending lowercase letters:
  • Suffix a: Designates the smaller cleavage fragment (typically released into the fluid phase as a soluble inflammatory mediator).
  • Suffix b: Designates the larger cleavage fragment (typically binds covalently to cell surfaces or participates directly in downstream convertase complexes).
  • Notable Historical Exception: For complement component C2, the larger, enzymatically active fragment that binds to the complex is designated C2a, while the smaller fragment released into solution is designated C2b.

• Alternative Pathway Naming:

  • Components of the alternative pathway are designated by capital letters and termed Factors (e.g., Factor B, Factor D, Factor H, Factor I, Factor P / Properdin).
  • Cleavage products append lowercase letters: for example, cleavage of Factor B generates smaller fragment Ba and larger active fragment Bb.

Initiation Mechanisms across Complement Pathways

• Classical Pathway Initiation:

  • Initiated when component C1q binds to target surfaces via three main mechanisms:
  1. Direct binding: C1q binds directly to bacterial surface structures (e.g., proteins or lipoteichoic acid).
  2. Acute-phase protein binding: C1q binds to C-reactive protein (CRP), which recognizes phosphocholine residues on bacterial polysaccharides.
  3. Antigen-Antibody complex binding: C1q binds to the Fc regions of antibodies complexed with antigens on pathogen surfaces (most potent activation mechanism).

• Lectin Pathway Initiation:

  • Initiated when soluble circulating carbohydrate-binding proteins recognize specific terminal sugar patterns on microbial surfaces:
  • Mannose-Binding Lectin (MBL): Binds mannose, fucose, and N-acetylglucosamine residues present in fungal, bacterial, protozoan, and viral envelope structures.
  • Ficolins: Bind N-acetylglucosamine residues on various microbial surfaces.

• Alternative Pathway Initiation:

  • Initiated independently of specific antibodies or lectins via low-level, continuous fluid-phase hydrolysis of C3 ("tickover").
  • Spontaneously generated plasma $C3b$ covalently attaches directly to non-self microbial surface molecules.

The Classical Pathway Biochemical Cascade

• Antibody Requirements:

  • Most potent in domestic animal species when driven by immunoglobulin M (IgM) or specific isotypes of immunoglobulin G (IgG).
  • A single pentameric IgM bound to antigen, or multiple closely spaced IgG molecules bound to antigen, exposes structural Fc binding sites for C1.

• Molecular Structure of the C1 Complex:

  • Exists in serum as a macromolecular complex represented as $C1q r_2 s_2$.
  • C1q Backbone: Consists of six identical collagen-like stalk domains terminating in globular head domains (resembling a bunch of tulips; "q" denotes its unique quaternary structure).
  • Associated Serine Proteases: Two molecules of C1r and two molecules of C1s are complexed with the C1q stalks.
  • C1r: The initial serine protease; cleaves and activates C1s.
  • C1s: The second serine protease; cleaves native C4 and C2.

• Step-by-Step Cascade Mechanism:
  1. C1 Binding and Activation: At least two globular heads of C1q must simultaneously bind to adjacent antibody Fc regions. This binding induces a conformational change that triggers autocatalytic cleavage of C1r. Active C1r then cleaves adjacent C1s molecules, activating C1s serine protease activity.

2. C4 Cleavage and Deposition: Active C1s cleaves fluid-phase C4 into small $C4a$ (released) and large $C4b$. Cleavage exposes a highly reactive thioester bond on $C4b$, allowing it to covalently bond to amine or hydroxyl groups on the nearby microbial surface.

3. C2 Cleavage and C3 Convertase Assembly: Active C1s cleaves native C2 into small $C2b$ and large $C2a$. The $C2a$ fragment binds to surface-bound $C4b$ to form $C4b2a$.
   • $C4b2a$ is the Classical Pathway C3 Convertase.

4. C3 Cleavage and Opsonization: $C4b2a$ rapidly cleaves abundant plasma C3 into small $C3a$ (anaphylatoxin) and large $C3b$. $C3b$ covalently attaches in massive quantities to the microbial surface, opsonizing the pathogen for phagocytosis.

5. C5 Convertase Assembly: A subset of generated $C3b$ molecules binds directly to the $C4b2a$ complex, forming $C4b2a3b$.
   • $C4b2a3b$ is the Classical Pathway C5 Convertase.
6. C5 Cleavage: $C4b2a3b$ cleaves native C5 into potent chemoattractant $C5a$ and larger fragment $C5b$, which remains surface-associated to initiate terminal Membrane Attack Complex formation.

The Lectin Pathway Cascade

• Structure and Recognition Molecules:
  • Operates as an antibody-independent innate mechanism.
  • Mannose-Binding Lectin (MBL): A tetrameric member of the C-type lectin family possessing significant structural homology to C1q.

• Ficolins: Plasma proteins containing fibrinogen-like domain structures that specifically bind N-acetylglucosamine.

• MASPs (MBL-Associated Serine Proteases):

  • Circulate complexed with MBL and Ficolins as zymogens (MASP-1, MASP-2).
  • Functionally analogous to C1r and C1s.

• Step-by-Step Cascade Mechanism:

  1. Binding of MBL or Ficolin to specific carbohydrate targets on microbial cell walls induces conformational changes.
  2. Conformational shift drives autocatalytic activation of associated MASPs.

3. Activated MASPs cleave native C4 into $C4a$ and $C4b$, and native C2 into $C2b$ and $C2a$.
4. $C4b$ and $C2a$ assemble on the pathogen surface to form $C4b2a$ (the Lectin Pathway C3 Convertase).
5. $C4b2a$ cleaves C3 into $C3a$ and $C3b$, depositing $C3b$ onto the pathogen.
6. Incorporation of $C3b$ generates $C4b2a3b$ (the Lectin Pathway C5 Convertase), initiating the terminal lytic sequence.

The Alternative Pathway Cascade and Amplification Loop

• Antibody and Lectin Independence:

  • Provides continuous, immediate innate surveillance without requiring specific antigen recognition or prior immunity.
  • Relies on continuous low-level fluid-phase spontaneous hydrolysis of plasma C3 ("tickover").

• Host Surface Protection vs. Microbial Activation:

  • Protection of Healthy Host Surfaces:
  • Normal host cell membranes express high densities of polyanions, sialic acid, and glycosaminoglycans.
  • Surface sialic acid promotes high-affinity binding of host regulatory Factor H to any spontaneously deposited $C3b$.
  • Factor H serves as an essential cofactor for Factor I, a plasma serine protease that cleaves $C3b$ into inactive $iC3b$, preventing complement cascade propagation on host tissues.

• Activation on Microbial Surfaces:

  • Microbial cell walls lack sialic acid and host regulatory polyanions.

  • In the absence of sialic acid, Factor H cannot bind deposited $C3b$.

  • Uninhibited surface $C3b$ binds plasma Factor B to form a $C3bB$ complex.

  • Plasma Factor D (an active circulating protease) cleaves Factor B within the complex, releasing fragment Ba and leaving active Bb bound to $C3b$.

  • $C3bBb$ forms the Alternative Pathway C3 Convertase.

  • Stabilization and the Amplification Loop:

• Unbound $C3bBb$ is unstable with a short half-life, but is stabilized by binding plasma Factor P (Properdin).

• The Amplification Loop: Active $C3bBb$ rapidly cleaves large quantities of plasma C3 into $C3a$ and $C3b$. Each newly generated $C3b$ can bind Factor B, undergo Factor D cleavage, and construct additional $C3bBb$ convertases. This feedback loop accounts for over 80% of total complement deposition regardless of the initiating pathway.

• C5 Convertase Generation:
  • As $C3b$ accumulation escalates on the microbial surface, a second $C3b$ molecule complexes with $C3bBb$ to form $C3bBb3b$.
  • $C3bBb3b$ is the Alternative Pathway C5 Convertase, which cleaves native C5 into $C5a$ and $C5b$.

Terminal Membrane Attack Pathway and MAC Assembly

• Biological Goal:

  • Construct a stable, macromolecular transmembrane protein pore across the target pathogen lipid membrane, causing cellular swelling, osmotic disruption, and direct lysis.

• Initiation:

  • Initiated when Classical/Lectin C5 convertase ($C4b2a3b$) or Alternative C5 convertase ($C3bBb3b$) cleaves C5 into soluble $C5a$ and surface-bound $C5b$.

• Sequential Step-by-Step MAC Assembly:

  1. C5b Binding: $C5b$ binds fluid-phase C6 and C7 to form a hydrophobic, soluble $C5b67$ complex.
  2. Membrane Insertion: Hydrophobic sites exposed on $C5b67$ insert into the hydrophobic core of the target lipid bilayer.
  3. C8 Binding: Native C8 binds to membrane-inserted $C5b67$, forming $C5b678$. C8 undergoes a structural transition unfolding a hydrophobic region that wedges deeply into the target membrane.
  4. C9 Polymerization: $C5b678$ binds, recruits, and induces conformational changes in multiple molecules of C9.
  5. Pore Formation: Between 10 to 16 copies of C9 polymerize end-to-end to build a rigid, open, cylindrical transmembrane channel known as the Membrane Attack Complex (MAC) or $C5b6789$.

• Mechanism of Lysis:
  • The open MAC pore creates an uninhibited conduit across the membrane.
  • Extracellular fluids, water, and ions rapidly rush into the target cell down osmotic gradients.
  • Massive influx of water induces osmodysregulation, ballooning, and complete osmotic lysis of the microbe.

Regulatory Mechanisms and Complement Control Proteins

• Physiological Importance of Regulation:

  • Uncontrolled or misdirected complement activation causes bystander destruction of host tissues, severe systemic inflammation, vascular damage, and shock.
  • Regulatory control proteins exist both in soluble circulating plasma forms and as membrane-bound host surface proteins to inhibit convertases and accelerate decay.

• Detailed Summary of Regulatory Control Proteins:

Clinical Correlations and Pathological Case Studies

• Cobra Venom Envenomation Case Study:
  • Venom of cobra snakes contains Cobra Venom Factor (CVF), a functional protein analogue of complement component $C3b$.
  • Mechanism of Pathogenesis:
  • CVF complexes with host plasma Factor B, which is cleaved by Factor D in the presence of Properdin to form $CVF \cdot Bb$.
  • $CVF \cdot Bb$ is a highly stable alternative-pathway C3/C5 convertase.
  • Crucially, $CVF \cdot Bb$ is completely resistant to host regulatory inactivation by Factor H and Factor I.
  • Leads to uninhibited, continuous cleavage of host C3 and C5, triggering systemic complement depletion and massive local inflammatory tissue damage.
  • Clinical Presentation:
  • Bites lead to extreme local tissue breakdown, vasodilation, edema, and necrosis.
  • Example: An 11-year-old boy presented with severe tissue necrosis two weeks following cobra envenomation (treated only with antibiotics), requiring above-knee limb amputation.
  • Snakebites in companion animals (such as cats) cause extensive tissue destruction and sloughing.

• Hereditary Canine Complement C3 Deficiency in Brittany Dogs:
  • Background:
  • In the 1980s, a research colony bred Brittany dogs to investigate hereditary canine spinal muscular atrophy.
  • Clinical Progression:
  • Age 2 years: Dogs developed pronounced susceptibility to recurrent severe bacterial infections and early kidney disease. Antibiotic treatment allowed most dogs to survive initial infection challenges.
  • Age 4–7 years: Affected dogs developed progressive mesangio-proliferative glomerulonephritis, leading to fatal renal failure.
  • Genetic Discovery: Colony dogs possessed an inherited homozygous genetic deficiency in Complement Protein C3.

• Pathophysiological Explanation:
  • Bacterial Infection Susceptibility: C3 is the mandatory convergence point for all three activation pathways. Absence of C3 prevents generation of $C3b$ (loss of opsonization and phagocytosis), prevents generation of $C3a$ and $C5a$ (loss of leukocyte recruitment/chemotaxis), and halts assembly of C5 convertases (loss of terminal MAC lysis). The immune system is rendered incapable of clearing bacterial pathogens.
  • Renal Disease / Glomerulonephritis: A vital physiological function of complement is immune complex clearance. $C3b$ coats circulating antigen-antibody complexes, binding them to CR1 receptors on erythrocytes for transport to the liver and spleen for degradation. Without C3, circulating immune complexes cannot be cleared; they precipitate out of circulation and deposit within the renal glomerular mesangium, driving chronic inflammatory mesangio-proliferative glomerulonephritis and renal failure.

Comprehensive Summary of Complement Activation Outcomes